{"schema_version":"secwatch.filing_event.v1","accession":"0002019410-26-000005","form_type":"8-K","ticker":"CAI","cik":"0002019410","company_name":"Caris Life Sciences, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.002439+00:00","generated_at":"2026-05-16T10:58:20.908353+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Caris Life Sciences reports preliminary Q4 2025 revenue of ~$281M, up 116% YoY; FY revenue ~$800M, up 94%","bullets":["Q4 revenue ~$281M (+116% YoY); Molecular Profiling services ~$270M including ~$81M prior-period true-ups.","Full-year 2025 revenue ~$800M (+94% YoY); Pharma R&D services ~$45M.","Q4 clinical therapy selection cases ~52,700 (+20%); full-year ~199,300 (+22%).","Cash, equivalents and marketable securities ~$802M as of Dec 31, 2025, up ~$43M from Sep 30, 2025.","Company presenting at 44th J.P. Morgan Healthcare Conference today; complete earnings call expected in late Feb 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0002019410-26-000005","json":"https://secwatch.observer/filing/0002019410-26-000005.json","markdown":"https://secwatch.observer/filing/0002019410-26-000005.md","text":"https://secwatch.observer/filing/0002019410-26-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000005/0002019410-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000005/cai-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:58:20.908353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}